Patent Issued for Aptamers as a therapeutic tool to prevent protein aggregation in neurodegenerative disease (USPTO 11814625).

A recent patent issued by Carleton University describes the use of aptamers as a therapeutic tool to prevent protein aggregation in neurodegenerative diseases such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. The patent focuses on an aptamer that binds to alpha-synuclein protein, which is associated with these diseases. The inventors propose using the aptamer to regulate or control alpha-synuclein aggregation, either by preventing aggregation or inducing deaggregation. This research has potential implications for the development of new treatments for these neurodegenerative diseases. [Extracted from the article]

Copyright of Gene Therapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)